Pfizer Inc. PFE announced that the FDA has granted approval to Mylotarg for adult patients with newly diagnosed CD33-positive acute myeloid leukemia (AML). The drug also received approval to treat ...

The prescribed dosage for Mylotarg (gemtuzumab ozogamicin) may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage of Mylotarg.

If you have a certain kind of cancer, your doctor might suggest Mylotarg as a treatment option. It’s a prescription drug used to treat acute myeloid leukemia (AML) in adults and some children.

Pfizer’s Mylotarg is back on the US market after a seven-year absence, after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody-drug ...

Mylotarg (gemtuzumab ozogamicin) is a brand-name drug that’s prescribed to treat certain types of acute myeloid leukemia in adults and some children. Mylotarg is given by intravenous infusion by a ...

After being on the market for 10 years and withdrawn for 7 years, Pfizer’s Mylotarg is set to make its return. The targeted acute myeloid leukemia drug on Friday won the FDA’s backing, again, marking ...

Pfizer Inc. PFE announced that the FDA’s Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia ...

Pfizer will have to cut the price of its leukaemia drug Mylotarg to get regular funding from the NHS, after England’s NICE said it could only be used in about 35% of eligible patients. NICE said it ...

Seven years after Mylotarg® (gemtuzumab ozogamicin) was voluntarily withdrawn from the market, the U.S. Food and Drug Administration has re-approved Mylotarg® product. Mylotarg® product was first ...

NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with chemotherapy. NICE is recommending Mylotarg for previously untreated, de novo ...

European regulators have cleared Pfizer’s Mylotarg to treat a certain subset of patients with acute myeloid leukaemia (AML). European regulators have cleared Pfizer’s Mylotarg to treat a certain ...

Pfizer has agreed to stop selling the cancer drug Mylotarg, an antibody-drug conjugate (ADC) that has been on the market since 2000. FDA made the request after recent clinical studies failed to show ...